The Role Of Rifaximin In The Chemoprophylaxis Of Travelers' Diarrhoea Particularly Aiming At The First 2 Weeks Of Travel: A Meta-Analysis Of 5 Randomized, Double-Blind, Controlled Trials

Xiao Zheng,Wen Kang,Shanyu Guo,Huihui Liu
2016-01-01
Abstract:The role of rifaximin in travelers' diarrhoea (TD) patients remains effective in major researches and needs further exploration. We pursued one meta-analysis to evaluate the efficiency of rifaximin on TD patients. So a systematic search of integrant databases was performed to identify RCTs comparing the use of rifaximin with placebo in TD patients. Results were expressed as risk ratios with accompanying 95% confidence intervals. This meta-analysis was accomplished with the fixed-effect in accordance with the heterogeneity. Then five studies involving 843 patients conformed our criteria. Rifaximin was associated with a reduction in the occurrence rate of classic travelers' diarrhoea (RR, 0.474; 95% CI, 0.369-0.608), classic travelers' diarrhoea during the first week (RR, 0.309; 95% CI, 0.196-0.487) and second week (RR, 0.477; 95% CI, 0.315-0.723) of travel. Furthermore during the first week of travel, rifaximin has a statistical better effect which directs the start time and duration of rifaximin use.
What problem does this paper attempt to address?